Reuters logo
BRIEF-Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy
November 20, 2017 / 12:12 PM / in 23 days

BRIEF-Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy

Nov 20 (Reuters) - Kamada Ltd:

* Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy

* Kamada Ltd - ‍Kamada now maintains full, worldwide commercial rights to its inhaled aat​

* Kamada - ‍ no financial implications related to termination of agreement for inhaled alpha-1 antitrypsin therapy Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below